Secondary deficiency of neuraminidase 1 contributes to CNS pathology in neurological mucopolysaccharidoses via hypersialylation of brain glycoproteins
Author:
Xu TianMeng, Heon-Roberts Rachel, Moore Travis, Dubot Patricia, Pan Xuefang, Guo Tianlin, Cairo Christopher W.ORCID, Holley Rebecca, Bigger Brian, Durcan Thomas M.ORCID, Levade Thierry, Ausseil Jerôme, Amilhon Bénédicte, Gorelik Alexei, Nagar Bhushan, Sturiale Luisa, Palmigiano Angelo, Röckle Iris, Thiesler Hauke, Hildebrandt Herbert, Garozzo Domenico, Pshezhetsky Alexey V.ORCID
Abstract
AbstractMucopolysaccharidoses (MPS) are lysosomal storage diseases caused by defects in catabolism of glycosaminoglycans. MPS I, II, III and VII are associated with lysosomal accumulation of heparan sulphate and manifest with neurological deterioration. Most of these neurological MPS currently lack effective treatments. Here, we report that, compared to controls, neuraminidase 1 (NEU1) activity is drastically reduced in brain tissues of neurological MPS patients and in mouse models of MPS I, II, IIIA, IIIB and IIIC, but not of other neurological lysosomal disorders not presenting with heparan sulphate storage. We further show that accumulated heparan sulphate disrupts the lysosomal multienzyme complex of NEU1 with cathepsin A (CTSA), β-galactosidase (GLB1) and glucosamine-6-sulfate sulfatase (GALNS) necessary to maintain enzyme activity, and that NEU1 deficiency is linked to partial deficiencies of GLB1 and GALNS in cortical tissues and iPSC-derived cortical neurons of neurological MPS patients. Increased sialylation of N-linked glycans in brain samples of human MPS III patients and MPS IIIC mice implicated insufficient processing of brain N-linked sialylated glycans, except for polysialic acid, which was reduced in the brains of MPS IIIC mice. Correction of NEU1 activity in MPS IIIC mice by lentiviral gene transfer ameliorated previously identified hallmarks of the disease, including memory impairment, behavioural traits, and reduced levels of the excitatory synapse markers VGLUT1 and PSD95. Overexpression of NEU1 also restored levels of VGLUT1-/PSD95-positive puncta in cortical neurons derived from iPSC of an MPS IIIA patient. Together, our data demonstrate that heparan sulphate-induced secondary NEU1 deficiency and aberrant sialylation of glycoproteins implicated in synaptogenesis, memory, and behaviour constitute a novel pathological pathway in neurological MPS spectrum crucially contributing to CNS pathology.Graphical abstract
Publisher
Cold Spring Harbor Laboratory
Reference91 articles.
1. Neufeld, E.F. ; Muenzer, J. The Mucopolysaccharidoses. In The Online Metabolic and Molecular Bases of Inherited Disease, Beaudet, A.L. , Vogelstein, B. , Kinzler, K.W. , Antonarakis, S.E. , Ballabio, A. , Gibson, K.M. , Mitchell, G. , Eds. The McGraw-Hill Companies, Inc.: New York, NY, 2014. 2. Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease 3. Mechanisms of neurodegeneration in mucopolysaccharidoses II and IIIB: analysis of human brain tissue 4. Neuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model 5. Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy
|
|